Can a Patient's own immune cells keep liver cancer at bay?
Disease control
Recruiting now
This trial tests whether giving patients their own activated T lymphocytes (ATL) after curative treatment for liver cancer can reduce the chance of the cancer coming back. The study enrolls adults with stage I, II, or IIIa hepatocellular carcinoma who have had or will have curati…
Phase 2 • Sponsor: Lukas Biomedical Inc. • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC